Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 08/02/2017 (Notice of voluntarily dismissal)

Filing Date: May 30, 2017

According to the Complaint, on April 13, 2017, Nexvet and Zoetis issued a joint press release announcing that they had entered into a Transaction Agreement (the "Merger Agreement") to sell Nexvet to Zoetis. Under the terms of the Merger Agreement, Zoetis will acquire all outstanding shares of Nexvet for $6.72 in cash per Nexvet common share (the "Merger Consideration"). The Proposed Transaction is valued at approximately $85 million.

On May 11,2017, Nexvet filed a Preliminary Proxy Statement on Schedule 14A (the "Proxy") with the SEC. The Complaint alleges the Proxy, which recommends that Nexvet stockholders vote in favor of the Proposed Transaction, omits and/or misrepresents material information concerning, among other things: (i) Nexvet's management's projections, utilized by the Company's financial advisor, Evercore Group L.L.C. ("Evercore") in its financial analyses; (ii) the valuation analyses prepared by Evercore in connection with the rendering of its fairness opinion; (iii) material omissions concerning Evercore's potential conflicts of interest; and (iv) material information concerning the sale process leading up to the Proposed Transaction.

On August 2, 2017, Plaintiff filed a Notice voluntarily dismissing this action.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Ireland


Ticker Symbol: NVET
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: N.D. California
DOCKET #: 17-CV-03099
JUDGE: Hon. Jon S. Tigar
DATE FILED: 05/30/2017
CLASS PERIOD END: 05/30/2017
  1. WeissLaw LLP (Beverly Hills)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available